Grimm E A, Silver H K, Roth J A, Chee D O, Gupta R K, Morton D L
Int J Cancer. 1976 May 15;17(5):559-64. doi: 10.1002/ijc.2910170503.
Spent tissue culture medium (CDM-S) removed from a single cell line of human malignant melanoma grown in serum-free CDM, contained tumor-associated antigenic activity. Antibodies to CDM-S measured by complement fixation were detected in 44% (31/70) melanoma, 55% (15/27) sarcoma, 63% (24/38) carcinoma and 15% (11/72) normal sera. Delayed cutaneous hypersensitivity reactions (DCHR) were demonstrated in 4/5 melanoma patients at a 500 mug dose, 3/5 at a 100 mug dose and in 1/7 carcinoma patients at the 500 mug dose. One ml of CDM-S was shown to contain antigen equivalent to that obtained from the membranes of 2.9 X 10(7) tissue-cultured melanoma cells. After purification, 84% (16/19) sera from melanoma patients, 66% (12/18) from sarcoma and carcinoma patients and 8% (2/26) from normal controls were positive to the antigen by complement fixation.
从在无血清细胞培养液(CDM)中培养的人恶性黑色素瘤单一细胞系中取出的用过的组织培养液(CDM-S)含有肿瘤相关抗原活性。通过补体结合法检测的针对CDM-S的抗体在44%(31/70)的黑色素瘤、55%(15/27)的肉瘤、63%(24/38)的癌以及15%(11/72)的正常血清中被检测到。在4/5的黑色素瘤患者中以500微克剂量、3/5的患者以100微克剂量以及1/7的癌患者以500微克剂量出现了迟发性皮肤超敏反应(DCHR)。1毫升CDM-S显示含有相当于从2.9×10⁷个组织培养的黑色素瘤细胞膜获得的抗原。纯化后,84%(16/19)的黑色素瘤患者血清、66%(12/18)的肉瘤和癌患者血清以及8%(2/26)的正常对照血清通过补体结合法对该抗原呈阳性反应。